Fulminant autoimmune Type 1 diabetes during interferon-alpha therapy: A case of Th1-mediated disease?

Emanuele Bosi, R. Minelli, E. Bazzigaluppi, M. Salvi

Research output: Contribution to journalArticle

Abstract

Aim: A case of autoimmune Type 1 diabetes with some unique characteristics developing in a 29-year-old male during treatment with interferon-alpha (IFN-α) for chronic hepatitis C virus (HCV) hepatitis is reported. Patient and methods: In this patient IFN-α treatment was well tolerated and successful in the cure of hepatitis with eradication of HCV infection within 3 months, but at 8.5 months Type 1 diabetes appeared and insulin therapy was started and maintained thereafter. HLA class II molecular typing was determined and retrospective measurement of islet cell (ICA), glutamate decarboxylase (GADA), tyrosin phosphatase IA-2 (IA-2A) and insulin (IAA) antibodies was performed in serum samples obtained before and at 0.5, 1, 2, 3, 4, 5, 6, 8.5, 10 and 13 months after the beginning of IFN-α treatment. Results: Complete HLA class II typing was consistent with homozygosity for the HLA DRB *03011, DQA1 *0501, DQB1 *0201 haplotype. All autoantibodies were undetectable prior to IFN-α therapy and remained undetectable up to 6 months of treatment; at 8.5 months, at the time of diabetes onset, ICA were detectable at low titre while GADA were present at high titre. Both ICA and GADA persisted at high levels in subsequent samples. IA-2A remained undetectable in all serum samples, while IAA appeared only after treatment with exogenous insulin. Discussion: This appears to be a case of autoimmune Type 1 diabetes induced by IFN-α treatment and developing on a predisposed genetic background with an unusually rapid development of the autoimmune process as reflected by the absence of detectable autoantibodies up to 2.5 months prior to disease onset. In this example of fulminant Type 1 diabetes a pathogenic process unbalanced towards a Th1-mediated autoimmune response is hypothesized.

Original languageEnglish
Pages (from-to)329-332
Number of pages4
JournalDiabetic Medicine
Volume18
Issue number4
DOIs
Publication statusPublished - 2001

Fingerprint

Type 1 Diabetes Mellitus
Interferon-alpha
Glutamate Decarboxylase
Therapeutics
Hepacivirus
Autoantibodies
Hepatitis
Dichlororibofuranosylbenzimidazole
Insulin
Insulin Antibodies
Molecular Typing
Chronic Hepatitis C
Virus Diseases
Serum
Autoimmunity
Islets of Langerhans
Phosphoric Monoester Hydrolases
Haplotypes

Keywords

  • Autoimmunity
  • HCV hepatitis
  • Interferon-alpha
  • Side-effects
  • Type 1 diabetes

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Fulminant autoimmune Type 1 diabetes during interferon-alpha therapy : A case of Th1-mediated disease? / Bosi, Emanuele; Minelli, R.; Bazzigaluppi, E.; Salvi, M.

In: Diabetic Medicine, Vol. 18, No. 4, 2001, p. 329-332.

Research output: Contribution to journalArticle

@article{b20d4c25edbc47808286c4fc1e9a13fb,
title = "Fulminant autoimmune Type 1 diabetes during interferon-alpha therapy: A case of Th1-mediated disease?",
abstract = "Aim: A case of autoimmune Type 1 diabetes with some unique characteristics developing in a 29-year-old male during treatment with interferon-alpha (IFN-α) for chronic hepatitis C virus (HCV) hepatitis is reported. Patient and methods: In this patient IFN-α treatment was well tolerated and successful in the cure of hepatitis with eradication of HCV infection within 3 months, but at 8.5 months Type 1 diabetes appeared and insulin therapy was started and maintained thereafter. HLA class II molecular typing was determined and retrospective measurement of islet cell (ICA), glutamate decarboxylase (GADA), tyrosin phosphatase IA-2 (IA-2A) and insulin (IAA) antibodies was performed in serum samples obtained before and at 0.5, 1, 2, 3, 4, 5, 6, 8.5, 10 and 13 months after the beginning of IFN-α treatment. Results: Complete HLA class II typing was consistent with homozygosity for the HLA DRB *03011, DQA1 *0501, DQB1 *0201 haplotype. All autoantibodies were undetectable prior to IFN-α therapy and remained undetectable up to 6 months of treatment; at 8.5 months, at the time of diabetes onset, ICA were detectable at low titre while GADA were present at high titre. Both ICA and GADA persisted at high levels in subsequent samples. IA-2A remained undetectable in all serum samples, while IAA appeared only after treatment with exogenous insulin. Discussion: This appears to be a case of autoimmune Type 1 diabetes induced by IFN-α treatment and developing on a predisposed genetic background with an unusually rapid development of the autoimmune process as reflected by the absence of detectable autoantibodies up to 2.5 months prior to disease onset. In this example of fulminant Type 1 diabetes a pathogenic process unbalanced towards a Th1-mediated autoimmune response is hypothesized.",
keywords = "Autoimmunity, HCV hepatitis, Interferon-alpha, Side-effects, Type 1 diabetes",
author = "Emanuele Bosi and R. Minelli and E. Bazzigaluppi and M. Salvi",
year = "2001",
doi = "10.1046/j.1464-5491.2001.00492.x",
language = "English",
volume = "18",
pages = "329--332",
journal = "Diabetic Medicine",
issn = "0742-3071",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Fulminant autoimmune Type 1 diabetes during interferon-alpha therapy

T2 - A case of Th1-mediated disease?

AU - Bosi, Emanuele

AU - Minelli, R.

AU - Bazzigaluppi, E.

AU - Salvi, M.

PY - 2001

Y1 - 2001

N2 - Aim: A case of autoimmune Type 1 diabetes with some unique characteristics developing in a 29-year-old male during treatment with interferon-alpha (IFN-α) for chronic hepatitis C virus (HCV) hepatitis is reported. Patient and methods: In this patient IFN-α treatment was well tolerated and successful in the cure of hepatitis with eradication of HCV infection within 3 months, but at 8.5 months Type 1 diabetes appeared and insulin therapy was started and maintained thereafter. HLA class II molecular typing was determined and retrospective measurement of islet cell (ICA), glutamate decarboxylase (GADA), tyrosin phosphatase IA-2 (IA-2A) and insulin (IAA) antibodies was performed in serum samples obtained before and at 0.5, 1, 2, 3, 4, 5, 6, 8.5, 10 and 13 months after the beginning of IFN-α treatment. Results: Complete HLA class II typing was consistent with homozygosity for the HLA DRB *03011, DQA1 *0501, DQB1 *0201 haplotype. All autoantibodies were undetectable prior to IFN-α therapy and remained undetectable up to 6 months of treatment; at 8.5 months, at the time of diabetes onset, ICA were detectable at low titre while GADA were present at high titre. Both ICA and GADA persisted at high levels in subsequent samples. IA-2A remained undetectable in all serum samples, while IAA appeared only after treatment with exogenous insulin. Discussion: This appears to be a case of autoimmune Type 1 diabetes induced by IFN-α treatment and developing on a predisposed genetic background with an unusually rapid development of the autoimmune process as reflected by the absence of detectable autoantibodies up to 2.5 months prior to disease onset. In this example of fulminant Type 1 diabetes a pathogenic process unbalanced towards a Th1-mediated autoimmune response is hypothesized.

AB - Aim: A case of autoimmune Type 1 diabetes with some unique characteristics developing in a 29-year-old male during treatment with interferon-alpha (IFN-α) for chronic hepatitis C virus (HCV) hepatitis is reported. Patient and methods: In this patient IFN-α treatment was well tolerated and successful in the cure of hepatitis with eradication of HCV infection within 3 months, but at 8.5 months Type 1 diabetes appeared and insulin therapy was started and maintained thereafter. HLA class II molecular typing was determined and retrospective measurement of islet cell (ICA), glutamate decarboxylase (GADA), tyrosin phosphatase IA-2 (IA-2A) and insulin (IAA) antibodies was performed in serum samples obtained before and at 0.5, 1, 2, 3, 4, 5, 6, 8.5, 10 and 13 months after the beginning of IFN-α treatment. Results: Complete HLA class II typing was consistent with homozygosity for the HLA DRB *03011, DQA1 *0501, DQB1 *0201 haplotype. All autoantibodies were undetectable prior to IFN-α therapy and remained undetectable up to 6 months of treatment; at 8.5 months, at the time of diabetes onset, ICA were detectable at low titre while GADA were present at high titre. Both ICA and GADA persisted at high levels in subsequent samples. IA-2A remained undetectable in all serum samples, while IAA appeared only after treatment with exogenous insulin. Discussion: This appears to be a case of autoimmune Type 1 diabetes induced by IFN-α treatment and developing on a predisposed genetic background with an unusually rapid development of the autoimmune process as reflected by the absence of detectable autoantibodies up to 2.5 months prior to disease onset. In this example of fulminant Type 1 diabetes a pathogenic process unbalanced towards a Th1-mediated autoimmune response is hypothesized.

KW - Autoimmunity

KW - HCV hepatitis

KW - Interferon-alpha

KW - Side-effects

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=0034950094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034950094&partnerID=8YFLogxK

U2 - 10.1046/j.1464-5491.2001.00492.x

DO - 10.1046/j.1464-5491.2001.00492.x

M3 - Article

C2 - 11437866

AN - SCOPUS:0034950094

VL - 18

SP - 329

EP - 332

JO - Diabetic Medicine

JF - Diabetic Medicine

SN - 0742-3071

IS - 4

ER -